Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag

Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag

Abstract Background Understanding patients’ perspectives regarding drug tolerability, in addition to effectiveness, provides a complete picture of the patient experience and supports more informed therapeutic decision-making. The item library of the National Cancer Institute’s Patient-Reported Outco...

Full description

Bibliographic Details
Main Authors: Stacy Davis, Teresa Edwards, Lindsey Norcross, Sheri Fehnel, Amélie Beaudet, Marie Eckart, John Fastenau
Format: Article
Language:English
Published: SpringerOpen 2023-12-01
Series:Journal of Patient-Reported Outcomes
Subjects:
Adverse events
Patient-reported outcomes
PRO-CTCAE
Pulmonary arterial hypertension
Selexipag
Side effects
Online Access:https://doi.org/10.1186/s41687-023-00673-w

Internet

https://doi.org/10.1186/s41687-023-00673-w

Similar Items